Physician profile
William D Ross
NPI 1669783064
$7,207.61
in general payments reported to CMS, 2019-2025
54 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what 77% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $580 · 2021: $566 · 2022: $1,278 · 2023: $1,544 · 2024: $832 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,238 · Travel and Lodging: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.97 |
| Travel and Lodging | $646.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,499.90 | 2019-2025 | Eterna, Proclaim |
| Medtronic, INC. | $1,107.62 | 2021-2023 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Synchromedii |
| Abbvie INC. | $403.27 | 2021-2025 | Ubrelvy, Qulipta |
| Boston Scientific Corporation | $399.43 | 2022-2025 | Wavewriter Alpha Prime 16, Patient Trial Kit |
| Stryker Corporation | $359.00 | 2019-2023 | Spinejack |
| Ucb, INC. | $314.36 | 2023-2025 | Fintepla, Rystiggo, Nayzilam |
| Nevro Corp. | $208.28 | 2019-2022 | |
| Argenx US, INC. | $184.33 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Collegium Pharmaceutical, INC. | $181.25 | 2020-2025 | Belbuca, Xtampza |
| Emd Serono, INC. | $180.18 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $173.28 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $156.70 | 2024-2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $131.01 | 2019-2021 | |
| Catalyst Pharmaceuticals, INC. | $111.84 | 2023-2025 | Fycompa |
| Spr Therapeutics, INC | $109.52 | 2021-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.